Trial Results

Protocol
Available Languages: English
Statistical Analysis Plan
Available Languages: English

Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study Identifier:
ACH471-100
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Danicopan
Date
Mar 2017 - Nov 2018
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Danicopan
Date
Mar 2017 - Nov 2018
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information

Protocol Summary

The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known as danicopan and ALXN2040) in currently untreated participants with PNH.

Trial Locations

Location
Status
Location
Clinical Trial Site
Florence, Italy
Status
N/A
Location
Clinical Trial Site
Naples, Italy
Status
N/A
Location
Clinical Trial Site
Seoul, Republic of Korea
Status
N/A
Location
Clinical Trial Site
Auckland, New Zealand
Status
N/A
Location
Clinical Trial Site
London, United Kingdom
Status
N/A